Why the study?
Anthracyclines are widely used in systemic chemotherapy, but dose-limiting cardiotoxicity can reduce cardiac function and increase heart failure risk.
What is the natural progression of left ventricular ejection fraction decline in patients receiving anthracyclines without cardioprotective therapy?
What is the natural progression of left ventricular ejection fraction decline in patients receiving anthracyclines without cardioprotective therapy?
While the mean LVEF decline following anthracyclines without cardioprotection is small (4.6%), a vulnerable subset of 16% experiences a clinically significant impairment.
Answers are grounded in this paper and cite their sources.
Anthracyclines reduce mean LVEF; confirms cardiotoxicity and supports routine cardiac monitoring in treated patients.
Background: Anthracyclines form the backbone of many systemic chemotherapy regimens but dose-limiting cardiotoxicity can also lead to reduction in cardiac function and an increased risk of heart failure. Methods: This review was conducted in accordance with PRISMA guidelines and registered on PROSPERO (CRD42022373496). Results: 26 studies met the eligibility criteria including a total of 910 patients. Overall reduction in pooled mean left ventricular ejection fraction (LVEF) post‐anthracyclines in the placebo arms of included randomised-controlled trials was 4.6% (95% CI, 2.7 to 6.6). The trend in LVEF showed a progressive decline until approximately 180 days after which there was no significant change. Those receiving a cumulative anthracycline dose 300 mg/m2 experienced a more profound reduction. The risk of a 10% absolute decline in LVEF from baseline or decline to an LVEF below 50%, the overall pooled risk was 16% (95% CI: 11 to 21; I2 = 77%). Sensitivity analyses by baseline LVEF and trastuzumab treatment status did not yield significant differences. Conclusion: While the mean LVEF decline in patients without cardioprotective therapy was clinically small, a vulnerable subset experienced significant impairment. Further research to best identify those who benefit most from cardioprotective therapies when receiving anthracyclines are required.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2022) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: